CO2020006951A2 - Formulaciones de fulvestrant y métodos de su uso - Google Patents
Formulaciones de fulvestrant y métodos de su usoInfo
- Publication number
- CO2020006951A2 CO2020006951A2 CONC2020/0006951A CO2020006951A CO2020006951A2 CO 2020006951 A2 CO2020006951 A2 CO 2020006951A2 CO 2020006951 A CO2020006951 A CO 2020006951A CO 2020006951 A2 CO2020006951 A2 CO 2020006951A2
- Authority
- CO
- Colombia
- Prior art keywords
- microns
- fulvestrant
- methods
- soluble excipient
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583403P | 2017-11-08 | 2017-11-08 | |
| PCT/US2018/059906 WO2019094650A1 (en) | 2017-11-08 | 2018-11-08 | Fulvestrant formulations and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020006951A2 true CO2020006951A2 (es) | 2020-06-19 |
Family
ID=64650494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0006951A CO2020006951A2 (es) | 2017-11-08 | 2020-06-05 | Formulaciones de fulvestrant y métodos de su uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12186427B2 (https=) |
| EP (1) | EP3706719A1 (https=) |
| JP (1) | JP7220712B2 (https=) |
| KR (1) | KR102670293B1 (https=) |
| CN (1) | CN111479556B (https=) |
| AU (1) | AU2018366212B2 (https=) |
| BR (1) | BR112020009141A2 (https=) |
| CO (1) | CO2020006951A2 (https=) |
| IL (1) | IL274433B2 (https=) |
| MA (1) | MA50570A (https=) |
| MX (2) | MX2020004792A (https=) |
| MY (1) | MY204442A (https=) |
| UA (1) | UA128158C2 (https=) |
| WO (1) | WO2019094650A1 (https=) |
| ZA (1) | ZA202002897B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4074304A4 (en) * | 2019-12-11 | 2024-01-10 | Shanghai Bocimed Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF |
| CN120284882A (zh) * | 2020-12-10 | 2025-07-11 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| KR20230094172A (ko) * | 2021-12-20 | 2023-06-27 | 주식회사 삼양홀딩스 | 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| HUP0400115A3 (en) * | 2001-07-07 | 2005-11-28 | Astrazeneca Ab | Pharmaceutical composition for the intramuscular administration of fulvestrant |
| PL1778187T3 (pl) | 2004-08-04 | 2012-09-28 | Camurus Ab | Kompozycje tworzące nielamelarne dyspersje |
| JP2006089386A (ja) * | 2004-09-21 | 2006-04-06 | Nippon Tenganyaku Kenkyusho:Kk | ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物 |
| CN101244029A (zh) * | 2006-03-28 | 2008-08-20 | 济南康泉医药科技有限公司 | 含雌激素受体拮抗剂的抗癌缓释注射剂 |
| CN1857217A (zh) * | 2006-03-28 | 2006-11-08 | 济南康泉医药科技有限公司 | 一种含雌激素受体拮抗剂的抗癌缓释注射剂 |
| JP2011514349A (ja) * | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| CN101525364B (zh) | 2008-03-07 | 2012-12-12 | 杭州九源基因工程有限公司 | 一种氟维司群的晶型及其制备方法 |
| AU2010278601A1 (en) * | 2009-07-31 | 2012-02-23 | Xi'an Libang Medical Technology Co., Ltd | Nanosphere or microsphere drug carrier, preparation method, composition and use thereof |
| EP2417975A4 (en) | 2009-08-31 | 2012-11-14 | Xi An Libang Medical Technology Co Ltd | FULVESTRANT NANOPERLENES / MICROPERLES AND MANUFACTURING METHOD AND USE |
| CA2811258C (en) | 2010-09-16 | 2019-10-15 | Shimoda Biotech (Pty) Ltd | Fulvestrant compositions and methods of use |
| ES2708302T3 (es) | 2011-05-20 | 2019-04-09 | Capital Business Y Gestion De Finanzas S L | Composición farmacéutica |
| ES2983451T3 (es) * | 2012-04-09 | 2024-10-23 | Eagle Pharmaceuticals Inc | Formulaciones de Fulvestrant |
| BR112014028376A2 (pt) * | 2012-06-08 | 2018-04-24 | Hoffmann La Roche | métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção |
| CN104782169B (zh) * | 2013-07-08 | 2019-06-28 | 华为技术有限公司 | 视频播放的控制方法、设备及系统 |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| JP2016529308A (ja) * | 2013-09-06 | 2016-09-23 | サラー ウッディン アハメド， | フルベストラント組成物 |
| US11590077B2 (en) * | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| IL285928B2 (en) * | 2016-05-06 | 2025-06-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
-
2018
- 2018-11-08 JP JP2020524855A patent/JP7220712B2/ja active Active
- 2018-11-08 KR KR1020207015889A patent/KR102670293B1/ko active Active
- 2018-11-08 CN CN201880080066.2A patent/CN111479556B/zh active Active
- 2018-11-08 MY MYPI2020002279A patent/MY204442A/en unknown
- 2018-11-08 WO PCT/US2018/059906 patent/WO2019094650A1/en not_active Ceased
- 2018-11-08 BR BR112020009141-3A patent/BR112020009141A2/pt unknown
- 2018-11-08 MX MX2020004792A patent/MX2020004792A/es unknown
- 2018-11-08 AU AU2018366212A patent/AU2018366212B2/en active Active
- 2018-11-08 IL IL274433A patent/IL274433B2/en unknown
- 2018-11-08 MA MA050570A patent/MA50570A/fr unknown
- 2018-11-08 EP EP18815404.1A patent/EP3706719A1/en active Pending
- 2018-11-08 UA UAA202003420A patent/UA128158C2/uk unknown
-
2020
- 2020-05-18 ZA ZA2020/02897A patent/ZA202002897B/en unknown
- 2020-06-05 CO CONC2020/0006951A patent/CO2020006951A2/es unknown
- 2020-07-13 MX MX2024010323A patent/MX2024010323A/es unknown
-
2023
- 2023-02-14 US US18/109,421 patent/US12186427B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021502362A (ja) | 2021-01-28 |
| BR112020009141A2 (pt) | 2020-10-27 |
| RU2020118559A3 (https=) | 2021-12-08 |
| CA3082193A1 (en) | 2019-05-16 |
| IL274433B1 (en) | 2024-03-01 |
| JP7220712B2 (ja) | 2023-02-10 |
| MA50570A (fr) | 2020-09-16 |
| MX2020004792A (es) | 2020-08-13 |
| ZA202002897B (en) | 2023-10-25 |
| US20230404918A1 (en) | 2023-12-21 |
| MY204442A (en) | 2024-08-28 |
| EP3706719A1 (en) | 2020-09-16 |
| CN111479556B (zh) | 2023-09-01 |
| CN111479556A (zh) | 2020-07-31 |
| UA128158C2 (uk) | 2024-04-24 |
| KR20200085809A (ko) | 2020-07-15 |
| AU2018366212B2 (en) | 2024-06-20 |
| AU2018366212A1 (en) | 2020-05-14 |
| KR102670293B1 (ko) | 2024-05-30 |
| IL274433B2 (en) | 2024-07-01 |
| US12186427B2 (en) | 2025-01-07 |
| MX2024010323A (es) | 2025-02-10 |
| IL274433A (en) | 2020-06-30 |
| WO2019094650A1 (en) | 2019-05-16 |
| RU2020118559A (ru) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020006951A2 (es) | Formulaciones de fulvestrant y métodos de su uso | |
| MX2017013590A (es) | Administracion de agente anticaspa soluble en surfactante. | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| MX2015013894A (es) | Composiciones de nanoparticulas novedosas. | |
| MX387604B (es) | Formulaciones cannabinoides estables. | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| MX2017000578A (es) | Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. | |
| MX2018015361A (es) | Formulacion de vacuna contra el vih. | |
| MX2018009298A (es) | Bomba de sistema de diálisis con conector. | |
| MX378901B (es) | Formulaciones liquidas estables de virus de vacuna. | |
| MX2020007356A (es) | Capsula de producto de higiene y sus metodos de uso. | |
| MX2018007933A (es) | Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina. | |
| WO2016130800A3 (en) | Pharmaceutical compositions comprising perillyl alcohol derivatives | |
| CO2020000328A2 (es) | Formulaciones a largo plazo | |
| EP3957655A4 (en) | ETHYLENE VINYL ALCOHOL COPOLYMER AND AQUEOUS SOLUTION WITH USE THEREOF | |
| CO2018013257A2 (es) | Formulaciones de fulvestrant y métodos para su uso | |
| MX391922B (es) | Composiciones para el cuidado oral | |
| PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| MX2019008845A (es) | Metodos y sistemas para mejorar la estabilidad de la formulacion prevapor de un dispositivo de vapeo electronico. | |
| CO2018003971A2 (es) | Suspensión acuosa para administración oral y método para su preparación | |
| MX2019008656A (es) | Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire. | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| CU20190019A7 (es) | Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer | |
| EP4364810A3 (en) | Topical formulations and uses thereof |